Armata Pharmaceuticals Overview
- Year Founded
-
1989
- Status
-
Public
- Employees
-
61
- Stock Symbol
-
ARMP
- Investments
-
3
- Share Price
-
$3.87
- (As of Friday Closing)
Armata Pharmaceuticals General Information
Description
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
Contact Information
Website
www.armatapharma.comCorporate Office
- 5005 McConnell Avenue
- Los Angeles, CA 90066
- United States
Corporate Office
- 5005 McConnell Avenue
- Los Angeles, CA 90066
- United States
Armata Pharmaceuticals Timeline
Armata Pharmaceuticals Stock Performance
As of 13-Nov-2026, Armata Pharmaceuticals’s stock price is $3.87. Its current market cap is $144M with 37.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.87 | $3.72 | $2.75 - $14.98 | $144M | 37.2M | 180K | -$3.14 |
Armata Pharmaceuticals Financials Summary
As of 30-Sep-2026, Armata Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 426,459 | 391,561 | 190,124 | 206,786 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (84,486) | (156,066) | (7,546) | (65,598) |
| Net Income | (110,646) | (173,799) | (18,916) | (69,045) |
| Total Assets | 84,478 | 76,882 | 86,437 | 98,363 |
| Total Debt | 251,583 | 288,018 | 126,515 | 120,371 |
Armata Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Armata Pharmaceuticals Comparisons
Industry
Financing
Details
Armata Pharmaceuticals Competitors (8)
One of Armata Pharmaceuticals’s 8 competitors is TechnoPhage, a Accelerator/Incubator Backed company based in Lisbon, Portugal.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TechnoPhage | Accelerator/Incubator Backed | Lisbon, Portugal | ||||
| iNtRON Biotechnology | Corporation | Seongnam, South Korea | ||||
| Kane Biotech | Corporation | Winnipeg, Canada | ||||
| Locus Biosciences | Venture Capital-Backed | Morrisville, NC | ||||
| Eligo Bioscience | Venture Capital-Backed | Paris, France |
Armata Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Armata Pharmaceuticals Patents
Armata Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240240387-A1 | Robotic device for washing, drying, and folding clothes | Pending | 18-Jan-2023 | ||
| AU-2022323171-A1 | Bacteriophages with improved antimicrobial activity | Pending | 02-Aug-2021 | ||
| CA-3227846-A1 | Bacteriophages with improved antimicrobial activity | Pending | 02-Aug-2021 | ||
| EP-4380586-A1 | Bacteriophages with improved antimicrobial activity | Pending | 02-Aug-2021 | ||
| EP-4380586-A4 | Bacteriophages with improved antimicrobial activity | Pending | 02-Aug-2021 | C12N7/00 |
Armata Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Armata Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Armata Pharmaceuticals Investments & Acquisitions (3)
Armata Pharmaceuticals’s most recent deal was a PIPE with Innoviva for . The deal was made on 17-Mar-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Innoviva | 17-Mar-2021 | PIPE | Biotechnology | ||
| AmpliPhi Biosciences | 10-May-2019 | Merger/Acquisition | Drug Discovery | ||
| Synthetic Genomics (Engineered bacteriophage assets) | 28-Feb-2018 | Corporate Asset Purchase | Buildings and Property |
Armata Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Armata Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| C3j Therapeutics. | Marina Del Rey, CA | 2016 |
Armata Pharmaceuticals FAQs
-
When was Armata Pharmaceuticals founded?
Armata Pharmaceuticals was founded in 1989.
-
Where is Armata Pharmaceuticals headquartered?
Armata Pharmaceuticals is headquartered in Los Angeles, CA.
-
What is the size of Armata Pharmaceuticals?
Armata Pharmaceuticals has 61 total employees.
-
What industry is Armata Pharmaceuticals in?
Armata Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Armata Pharmaceuticals a private or public company?
Armata Pharmaceuticals is a Public company.
-
What is Armata Pharmaceuticals’s stock symbol?
The ticker symbol for Armata Pharmaceuticals is ARMP.
-
What is the current stock price of Armata Pharmaceuticals?
As of 13-Nov-2026 the stock price of Armata Pharmaceuticals is $3.87.
-
What is the current market cap of Armata Pharmaceuticals?
The current market capitalization of Armata Pharmaceuticals is $144M.
-
Who are Armata Pharmaceuticals’s competitors?
TechnoPhage, iNtRON Biotechnology, Kane Biotech, Locus Biosciences, and Eligo Bioscience are some of the 8 competitors of Armata Pharmaceuticals.
-
What is Armata Pharmaceuticals’s annual earnings per share (EPS)?
Armata Pharmaceuticals’s EPS for 12 months was -$3.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
